Business Description
Checkpoint Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1628282063
Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -2.43 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -118.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -70.3 | |||||
| 3-Year EBITDA Growth Rate | 12.5 | |||||
| 3-Year EPS without NRI Growth Rate | 8.1 | |||||
| 3-Year FCF Growth Rate | 5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.94 | |||||
| 9-Day RSI | 40.7 | |||||
| 14-Day RSI | 44.28 | |||||
| 6-1 Month Momentum % | 77.05 | |||||
| 12-1 Month Momentum % | 92.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.29 | |||||
| Quick Ratio | 0.29 | |||||
| Cash Ratio | 0.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -58.7 | |||||
| Shareholder Yield % | -14.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -79817.02 | |||||
| Net Margin % | -98868.09 | |||||
| FCF Margin % | -63906.82 | |||||
| ROA % | -763.77 | |||||
| ROIC % | -2671.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3640 | |||||
| EV-to-EBIT | -4.48 | |||||
| EV-to-Forward-EBIT | -3.17 | |||||
| EV-to-EBITDA | -4.48 | |||||
| EV-to-Forward-EBITDA | -3.17 | |||||
| EV-to-Revenue | 3577.96 | |||||
| EV-to-Forward-Revenue | 543.53 | |||||
| EV-to-FCF | -5.47 | |||||
| Earnings Yield (Greenblatt) % | -22.32 | |||||
| FCF Yield % | -17.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Checkpoint Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.044 | ||
| EPS (TTM) (€) | -1.687 | ||
| Beta | 1.06 | ||
| Volatility % | 79.12 | ||
| 14-Day RSI | 44.28 | ||
| 14-Day ATR (€) | 0.258042 | ||
| 20-Day SMA (€) | 3.755 | ||
| 12-1 Month Momentum % | 92.97 | ||
| 52-Week Range (€) | 1.286 - 4.2 | ||
| Shares Outstanding (Mil) | 48.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Checkpoint Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Checkpoint Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Checkpoint Therapeutics Inc Frequently Asked Questions
What is Checkpoint Therapeutics Inc(FRA:CZTA)'s stock price today?
The current price of FRA:CZTA is €3.20. The 52 week high of FRA:CZTA is €4.20 and 52 week low is €1.29.
When is next earnings date of Checkpoint Therapeutics Inc(FRA:CZTA)?
The next earnings date of Checkpoint Therapeutics Inc(FRA:CZTA) is 2025-03-21 Est..
Does Checkpoint Therapeutics Inc(FRA:CZTA) pay dividends? If so, how much?
Checkpoint Therapeutics Inc(FRA:CZTA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers